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ABSTRACT
The use of a porcine model in assessing bone grafts in vivo is common when a large animal
model is necessary. In this thesis we aimed to improve the porcine model of facial
reconstruction through the use of a local anesthesia and novel methods of assessing the immune
response to and bone forming ability of adult adipose derived mesenchymal stromal cells (ASC).
The goals of the research were: 1) evaluate the effect of a bupivacaine mandibular nerve block
on blood pressure (BP) and heart rate (HR) in response to surgical stimulation and the need for
systemic analgesics postoperatively, 2) quantify circulating T and B cell populations, 3) measure
serum levels of biomarker for bone metabolism; 4) assess correlations between circulating
biomarkers and surgical site bone volume and surface area.
14 adult, male Yucatan miniature pigs were utilized for the studies. The anesthesia study
separated the pigs equally between two groups: saline control and bupivacaine nerve block. BP
and HR were monitored during surgery and a custom ethogram was used to assess pain
postoperatively. The ASC study assigned the pigs to three groups: no implant (NI), bovine
xenograft (S), and bovine xenograft with autogenous ASCs (ASC). Characterization of
peripheral lymphocyte populations was done with flowcytometry using antibodies against
porcine CD4, CD8, CD3, and CD21. Six ELISA kits for biomarkers of bone remodeling were
used to measure serum levels.
The anesthesia study demonstrated improved surgical HR and BP control with a bupivacaine
mandibular block in conjunction with systemic analgesics but no improvement in postoperative
analgesia.
In the graft response study, the ASC group demonstrated significantly lower levels of circulating
CD4+/CD8+, CD4+/CD8-, and CD3+/CD4+ lymphocyte populations. Serum levels of
Carboxy-terminal cross-linked telopeptide of type I collagen were significantly elevated in the
v

ASC group while levels of osteocalcin were lower. Bone specific alkaline phosphatase was
significantly lower in both the ASC and S groups compared to NI.
The findings in these studies help to improve how we utilize the porcine model and will help
lead to a better understanding of the immune system and biomarker response in pigs.
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CHAPTER 1: LITERATURE REVIEW
1.1

Adipose Derived Multipotent Stromal Cell Introduction
1.1.1 Multipotent Stromal Cell Definition and Nomenclature

The area of regenerative medicine has been very active in research in recent years. The
discovery of adult multipotent mesenchymal stromal cells has taken this field of research in new
directions without the stigma associated with embryonic stem cells. Multipotent mesenchymal
stromal cells (MSCs) originate from different connective tissues including bone (1), adipose (2),
skin (3), muscle (4), umbilical cord (5), corneal stroma (6), and periosteum (7). MSCs have
recently been described as having many similarities to pericytes as they are thought to be of
perivascular origin (8). This helps explain their extreme abundance in multiple tissue sources.
These cells are readily available and have the ability to differentiate into multiple tissues
including bone, adipose, muscle, and neural tissue (9). The International Society for Cellular
Therapy proposed three minimal criteria to define human MSCs. First, plastic-adherence must be
demonstrated by MSCs when maintained in standard culture conditions. Second, expression of
CD105+, CD73+ and CD90+ must be present while lacking expression of CD45-, CD34-,
CD14- or CD11b-, CD79α- or CD19- and HLA-DR surface molecules. Third, triliniage
differentiation in vitro must be demonstrated through differentiation into osteoblasts, adipocytes
and chondroblasts (10).
The nomenclature used when discussing MSCs has been, for the most part, standardized over the
last few years. Having multiple tissue sources for cells requires different nomenclature
dependent upon the tissue of origin. The majority of articles are focused on stromal cells from
bone marrow (BMSC) or adipose tissue (ASC). The term “multipotent mesenchymal stromal
cell” is currently preferred over “adult stem cell” as these cells do not have the same
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differentiating characteristics as pluripotent stem cells. When these cells are collected from
tissue they are usually mixed in with other cell types. In the case of ASCs this mixture is called
the stromal vascular fraction (SVF) and it consists mainly of pericytes, hematopoietic-lineage
cells, ASCs, and fibroblasts (11). Purification of MSCs is usually accomplished after culturing
to eliminate nonadherent cells. Culturing MSCs produces colony-forming units (CFU), used to
measure cell frequency in tissues, each of which is initiated from a single MSC (12, 13).
1.2

Therapeutic Effects Of Adipose Derived Multipotent Stromal Cells
1.2.1 Differentiation Capabilities Of Adipose Derived Multipotent Stromal Cells

ASCs meet the criteria set by the International Society for Cellular Therapy in their
differentiation capabilities. In vitro ASCs have demonstrated adipogenic, osteogenic,
chondrogenic, and myogenic differentiation (14). Each pathway to differentiation is induced by
specific culture media. Osteogenic differenciation is usually accomplished using a mixture of
ascorbic acid, dexamethasone, and β-Glycerophosphate (15). Other components can be
substituted or added including vitamin D3 and ascorbate-2-phosphate (11, 14, 15).
Dexamethasone induces Runx2 expression by FHL2/β-catenin-mediated transcriptional
activation and enhances Runx2 activity thus promoting osteoblast differentiation. Ascorbic acid
leads to the increased secretion of collagen type I and the phosphate from β-Glycerophosphate
serves as a source for the phosphate in hydroxylapatite (15). Modalities used to confirm
osteogenic differentiation include: histochemical analysis using BM Purple, alizarin red, ALP
assay or von Kossa stain; mRNA of BGLAP, ALP, COL1A1, or RUNX2 (14).
1.2.2 Trophic Effects Of Adipose Derived Multipotent Stromal Cells
The trophic effect of ASCs refers to their ability to promote cell growth, differentiation, and
survival beyond their direct differentiation capabilities. There are a number of factors secreted
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by ASCs which aid in the survival and expansion of surrounding tissues. Vascular endothelial
growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF-2), and
transforming growth factor beta (TGF-β) are secreted by ASCs and have been shown to promote
angiogenesis and wound healing (11). These mechanisms improve ASCs ability to be used in
regenerative medicine. By promoting survival and growth of surrounding tissues, ASCs may
improve the integration of implants and grafts into the host tissues.
1.2.3 Immune Modulatory Effects Of Adipose Derived Multipotent Stromal Cells
One of the largest hurdles to overcome in the long term survival of a graft or implant is the
immune system response. The ability to completely bypass this problem using autologous tissue
is not always feasible due to the limited supply and possible donor site morbidity. ASCs show
great promise in addressing this issue through tissue engineering due to the ready supply and
easy accessibility of adipose tissue. Immune privilege and regulation has also been demonstrated
by ASCs through a multitude of secreted factors and cell-cell binding. This ability has been
demonstrated clinically with the control of graft-versus-host disease (GVHD)(16-18), colitis
(19), arthritis (20), and other autoimmune diseases (21).
The mechanisms by which ASCs can control the immune response are vast and depend on the
application. ASCs can act on both adaptive an innate immune systems by T cell suppression,
reduction in natural killer cell (NK) proliferation and cytotoxicity, promotion of regulatory T
cells (Treg), reducing B cell proliferation and activation, and reducing dendritic cell maturation
(20, 22-24). When it comes to graft acceptance, T cells are the main target for therapy as they
are the primary mediator of graft rejection.
The suppression of T cell expansion in vitro by ASCs has been well described in the literature.
ASCs are believed to have anti-inflammatory and immune-modulating properties which have
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been associated with inhibition of T-cell activation and possible increase in regulatory T cell
(Treg) numbers (20, 22, 23, 25). The suppressive effects of ASCs on T-cell populations have
been consistently demonstrated on both CD4+ T helper (Th) cells and CD8+ cytotoxic T
lymphocytes.(26) Cell to cell contact and release of soluble factors have been shown to attribute
to ASC mediated T cell suppression (27-29). Multiple potential mediators have been identified:
protoglandin E2 (PGE2), indoleamine-2,3-dioxgenase (IDO), nitric oxide, IL-10, IL-6,
transforming growth factor-beta (TGF-β) (9, 24, 26, 30). The multitude of pathways in which
ASCs modulate or suppress the immune system helps to explain why they can be advantageous
in different disease processes.
1.3

Bone Remodeling And Grafting
1.3.1 Physiology And Biology Of Bone Remodeling

Bone remodeling is an ongoing process with in the skeletal structure to maintain the health and
structural strength of bone. Remodeling of bone is controlled by a balance between osteoclast
and osteoblast activity which resorb old, microdamaged bone and form new bone respectively.
This process is continuous in healthy bone at a rate to maintain homeostasis and varies
depending on bone type. Cortical bone remodels at a slower rate than trabecular bone. The
process can also respond to changes in mechanical loading and demand.
Bone remodeling generally occurs in an ordered series of events: activation, resorption, reversal,
and formation. Activation refers to the initial process of forming and activating multinucleated
preosteoclasts and their binding to bone matrix. Osteoclasts are regulated by NF-κB (RANKL),
IL-1 and IL-6, colony stimulating factor (CSF), parathyroid hormone, vitamin D, and calcitonin
(31). Hydrogen ions secreted by osteoclasts lower the pH within the bone-resorbing
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compartment to help mobilize bone minerals (32). Once osteoclast bone resorption has begun it
takes approximately 2 to 4 weeks, in humans, until the reversal process begins.
The reversal phase is the transition from bone resorption to bone formation. Bone resorption
cavities contain monocytes, osteocytes, and preosteoblasts for new bone formation. The exact
signals which trigger the transition from resorption to formation have not been identified.
Transforming growth factor beta (TGF-β) from bone matrix can inhibit RANKL production and
decrease osteoclast resorption (33).
Formation of bone is carried out by osteoblasts. Bone progenitor cells, pre-osteoblasts, are
located in the endosteum, periosteum, and Haversian canals. These cells are stimulated through
growth factors (BMP, FGF, IGF, platelet-derived growth factor (PDGF), and interleukins) to
proliferate into osteoblasts. Three stages are involved in osteoblast differentiation: proliferation,
matrix maturation, and mineralization. The proliferation stage includes secretion of extra
cellular matrix (ECM) proteins by osteoblasts to form non-mineralized bone matrix or osteoid.
Matrix maturation occurs when the osteoid proteins are crosslinked to form a more stable
structure. The crosslinked collagen type I fibrils act as templates for deposition of inorganic
minerals to form the mineralized bone matrix. Calcium and phosphate are concentrated while
mineralization inhibitors such as pyrophosphate or proteoglycans are destroyed (34). Once
osteoblasts have become surrounded by matrix they can become embedded osteocytes, inactive
osteoblasts and become bone lining cells, or undergo apoptosis. Approximately 50 to 70% of
osteoblasts undergo apoptosis at completion of bone formation.
1.3.2 Bone Graft Models And Nomenclature
Bone grafts are used commonly for orthopedic defects which are at risk of not healing without
intervention, commonly called critical size defects. Other terms often used are “nonhealing” or
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“nonunion”. Critical size defects cannot be completely defined by size as bone is an anisotropic
material and healing will vary between location, surrounding tissue damage, and use. The
majority of models used to study treatment for such defects involve rodents using a calvarial
defect or spinal fusion model (35). The defects are made in the parietal bone with the size
varying from 4mm in mice to up to 8mm in rats (36-39). Models in larger animals can utilize the
flat bones of the skull (40) or long bones (41, 42).
Grafts are categorized based on the donor species as it relates to the host. Autologous grafts are
intra person grafts for which the same person is the recipient and donor. These grafts are seen as
gold standard due to the lack of immune rejection. Allogeneic grafts are between two
individuals of the same species. Allogeneic grafts are used commonly in humans from cadavers
and carry risk of immune rejection or disease transmission. Xenogeneic grafts occur when the
donor and recipient are of different species. Xenografts are associated with severe immune
responses if not properly processed before implantation. If preparation of this type of graft could
be perfected it would be a huge step toward alleviating the shortage of available grafts. If two
individuals are identical genetically, such as inbred mice or some identical twins, a graft between
them is known as syngeneic and is usually well accepted.
1.3.3 Bone Graft Healing
The ability of a bone graft to incorporate into existing tissue is dependent on three main
functions of the graft material and host tissue: osteogenesis, osteoconduction, and
osteoinduction.
Osteogenesis refers to the direct formation of new bone. To perform osteogenesis, a bone graft
requires living cells. Oseoblasts or pre-osteoblasts must be present within the graft in order for
the graft to directly contribute to osteogenesis within the recipient (43). Pre-osteoblasts are
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believed to contribute more to the new bone formation if a nonvascularized graft is used. These
pre-osteoblasts are found in bone marrow, periosteum and endosteum.
The ability of a graft to provide structural framework on which host cells reconstitute is known
as osteoconduction (44). Union with the host bone begins with ingrowth of vessels, osteoblasts,
and stem cells from the host into the graft. Structural properties which influence the
osteoconductive capabilities of graft material include porocity, pore size, pore connectivity, and
surface topography (45). Factors which can restrict osteoconduction are defect size, recipient
bed cellularity, host resorption and remodeling, and contact with donor tissue.
Osteoinduction refers to recruitment of progenitor cells from the host tissue into the graft where
they can differentiate to osteoblasts (46). This could also be defined as the process by which
osteogenesis is induced. An ideal osteoinductive material will function on three key principles:
1) Recruitment of MSCs, 2) MSC differentiation to osteoblasts, and 3) Ectopic bone formation
(47). Any material or graft which can display these three principles should display good
osteoinduction.
All three of the previously described function would be well demonstrated by an ideal bone graft.
A deficiency in one area can cause problems in a grafts ability to properly incorporate into the
recipient tissue. Appropriate integration is key to having a well-tolerated and functional graft.
1.4

Serum Biomarkers Of Bone Remodeling
1.4.1 Serum Biomarkers

Research involving the treatment of bone defects is reliant on the ability to assess bone growth.
Having the ability to monitor the growth of bone in a noninvasive manner allows for the
collection of more data without increasing the number of animals used in research. It also allows
for monitoring of treatments in humans. Noninvasive modalities in monitoring bone remodeling
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include radiographs, magnetic resonance imaging (MRI), computerized tomography (CT) scans,
bone scintigraphy scan, and serum biomarkers. Clinically in humans a bone density scan is done
for women who are at risk for osteoporosis. Imaging modalities similar to this are very useful
but carry certain risks if repeated too frequently due to the exposure to radiation with MRI being
the exception. These imaging techniques can also be cost prohibitive serial images are required.
Systemic biomarkers have shown promise as a method to frequently assess skeletal structural
changes over time.
A serum biomarker of bone remodeling is a biologic marker detectable in the serum that may be
used to measure the presence or progress of bone remodeling due to disease or treatment. The
biomarkers for bone are generally molecular structures released from tissue or cells in the
process of remodeling bone. The majority of markers target osteoclast or osteoblast activity and
products from the breakdown or synthesis of collagen. Such biomarkers have been studied to
assess bone turnover as it relates to multiple diseases: metastatic cancer involving bone,
osteoarthritis, osteoporosis, primary hyperparathyroidism, and osteodystrophy to name a few
(48-52). Many of the markers investigated are not useful as a single diagnostic technique, but
they can be helpful in monitoring at risk patients. Tang et al reported serum levels of bone
alkaline phosphatase (BAP) and type I collagen carboxyterminl telopeptide (ICTP) to be
significantly higher in lung cancer patients with bone metastasis (50). The current thought is that
there isn’t one biomarker that is useful alone but possible patterns in multiple biomarkers may be
helpful in predicting disease (53).
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CHAPTER 2: THE EFFECT OF A BUPIVACAINE MANDIBULAR NERVE BLOCK
ON INTRAOPERATIVE CHANGES IN BLOOD PRESSURE AND HEART RATE AND
THE NEED FOR POST-OPERATIVE ANALGESICS IN A YUCATAN MINIATURE
SWINE MANDIBULAR CONDYLECTOMY MODEL: A PILOT STUDY
2.1

Introduction

Animal models are a priceless resource when developing new techniques and treatments for
human medical application. In some instances, the ability to improve an animal model comes
from established procedures in humans. This holds especially true for the implementation of
local nerve blocks. The information gathered from human patients on dose, duration and extent
of pain relief provided by local nerve blocks is a basis for improved analgesia in animal models.
Miniature swine are used extensively in the development of dental, oral and maxillofacial
surgical techniques due to similarities to humans in anatomy, healing, and remodeling (40, 5457). There is a lack of literature describing local anesthetic techniques in miniature pig models
for oral and maxillofacial surgery, though this form of analgesia is common in human patients
undergoing the same procedures (57). As with every animal surgical model, the quest for the
most effective anesthetic and analgesic regimens is a top priority for animal health and wellbeing.
Local nerve blocks are an established and effective method for pain control in oral and
maxillofacial surgical procedures (58). Their local action, prolonged analgesia and limited side
effects make them an appealing alternative to systemic analgesics such as opioids. Bupivacaine
(0.5%) nerve blocks alone are reported to last between 2 and 12 hours in animals and humans
(59, 60). The mandibular nerve is the largest branch of the trigeminal nerve. It has both motor
and sensory function, with branches innervating the muscles of mastication and mandibular
teeth. The nerve exits the skull through the foramen ovale and runs cranial and ventral toward
the mandibular foramen where the inferior alveolar nerve enters. The anatomy of the miniature
9

pig mandibular nerve has not been extensively studied but is assumed to be similar to that of
other mammals (61). A local mandibular nerve block has been shown to provide relief from
bone and soft tissue pain in humans and animals undergoing dental procedures (58, 62-64). A
proximal mandibular nerve block eliminated the need for intraoperative analgesia and provided
postoperative analgesia for 8 hours in a canine patient undergoing a rostral mandibulectomy (63).
Pain relief is important both for post-operative comfort and healing. Self-trauma from licking,
scratching or rubbing a surgical site in response to pain impairs healing. Stress from postoperative surgical pain has also been linked to delayed wound healing in multiple models (65,
66). Release of glucocorticoids and catecholamines as well as a decrease in local cytokines and
cellular infiltrates from stress can impair wound healing (65). Improving postoperative analgesia
can decrease discomfort and stress in animal surgical models.
This study utilized Yucatan miniature pigs as a model for mandibular condylectomy and implant
surgery. The aim was to determine the efficacy of a 0.5% bupivacaine mandibular nerve block
for intra- and postoperative analgesia in the Yucatan miniature pig model. We hypothesized that
a mandibular nerve block with bupivacaine: (1) decreases the need for systemic analgesia during
mandibular condylectomy and implant surgery compared to saline in a porcine model and (2)
decreases postoperative signs of pain.
2.2

Materials And Methods
2.2.1 Animals And Husbandry

This study was performed at the Louisiana State University School of Veterinary Medicine , an
AAALAC International accredited facility, in accordance with the Guide for the Care and Use
of Laboratory animals (67). All experimental procedures were approved by the IACUC.
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Fourteen male castrated Yucatan miniature pigs (Sus scrofa domestica) were certified to be free
from common domestic swine diseases (leptospirosis, brucellosis, pseudorabies, transmissible
gastroenteritis, porcine reproductive respiratory syndrome and toxoplasmosis) and current on
Mycoplasma hyopneumoniae bacterin (M + Pac) vaccine by the supplier, Sinclair Bio-Resources
(Columbia, MO). All pigs were skeletally mature (mean age, 24.7 months; range, 20 to 32
months). They were housed in groups of 4 to 5 in an ambient temperature facility within 124
inch by 84 inch pens with rubber padded flooring covered by about 2 inches of pine shavings
(S&S Farms, Inc, Franklinton, LA). A radiant heat source was supplied when ambient
temperatures decreased below 50°F (10°C). Pigs were offered Mazuri mini pig active adult diet
(Land O’Lakes, Inc, Saint Paul, MN) twice daily in one trough per two pigs, and they had
unrestricted access to water for the duration of the study. Pigs were allowed to acclimate to their
new environment for 7 days prior to initiation of the study, and they were housed singly for
about 18 hours after surgery before being returned to their established social groups.
2.2.2 Experimental Groups
All pigs underwent left mandibular condylectomy surgery as part of an implant study. Prior to
the surgical procedure each pig was randomly assigned to one of two treatment groups. One
cohort (n=7) received a bupivicaine mandibular nerve block while the other cohort (n=7)
received an equal volume of saline at the mandibular nerve block injection site. Within each
treatment cohort, condylectomies were performed on all pigs and implants were placed in six
(one received a condylectomy only in each group).
Anesthesia Protocol: After 12 hours of food withdrawal, pigs were chemically restrained with
ketamine (10mg/kg, Vedco Inc; St. Joseph, MO), midazolam (0.2mg/kg, Hospira, Inc;
Lakeforest, IL), and dexmedetomidine (2ug/kg, Pfizer Animal Health, NY, NY) administered
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intramuscularly. Fifteen minutes later, anesthesia was induced with 5% isoflurane in 100%
oxygen at 1.5 L/minute flow via facial mask. When muscle relaxation characterized by loss of
jaw tone and palpebral reflexes was observed, the trachea was intubated with a cuffed Murphy’s
endotracheal tube (7-9 mm internal diameter). Anesthesia was maintained in all pigs at a
vaporizer setting of 1.5% isoflurane in a circular breathing system until the end of the surgery.
Continuous heart rate (HR) and blood pressure (BP) recordings were performed perioperatively
on all pigs. Blood pressure was measured in 8 pigs through an arterial line placed in the auricular
artery. Arterial line placement was not possible in 6 pigs (2 from the bupivacaine group, 4 from
the control group), so blood pressure was monitored with a non-invasive blood pressure (NIBP)
cuff on the mid metatarsus. Data from the NIBP cuff was not included in the statistical analysis
due to differences between invasive and noninvasive BP monitoring techniques.(68-70) Mean
values and standard deviations were calculated from continuous BP and HR data within
segments corresponding to 1 minute before the surgical incision (baseline), 1 minute prior to
rescue analgesia (pre-rescue) and for 1 minute at both 10 and 20 minutes post-rescue. These
readings included only the condylectomy portion of the surgery in all pigs. Data from the implant
portion of the surgery were not included in the analysis.
2.2.3 Nerve Block and Rescue Analgesia
After anesthesia was induced, pigs were placed in right lateral recumbency and the left jaw
prepared for surgery. Following aseptic preparation, pigs were randomized to receive a
mandibular block with an equal volume of either 0.5% bupivacaine (Hospira, Inc: Lakeforest,
IL) (0.4 mg/kg, bupivacaine group) or saline (volume based on bupivacaine calculation, control
group). 5 mL was the average volume used. Bupivacaine was selected based on the experience
of the anesthesiologist and for its longer duration of action compared to lidocaine. The person
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administering the block was not blinded to treatment. For the mandibular block, an insulated
10cm, 20G needle was inserted medial to the left mandibular ramus at the point of the angle of
the mandible and advanced toward the lateral canthus of the ipsolateral eye with the aid of a
nerve stimulator (Pajunk, MultiStim Sensor, Germany) to identify the injection site (Figure 1).
The nerve stimulator was set to deliver a 1 mA impulse. When movement of the mandible was
noted, signaling stimulation of the muscles of mastication, the impulse was reduced to 0.4 mA.
If mandibular movement was sustained at 0.4 mA the treatment was administered through the
stimulator needle. Protocol for administration of the block was based on the anesthesiologist’s
experience and expertise.
After the mandibular block, pigs were assigned to 2 different surgical procedures involving a left
mandibular condylectomy. During the surgery, a rescue analgesic protocol consisting of fentanyl
(Hospira, Inc; Lakeforest, IL) and lidocaine (Sparhawk laboratories, Inc; Lenexa, KS) was
instituted if BP or HR increased 20% above baseline values. For rescue analgesia, a bolus of
fentanyl (5mg/kg) and lidocaine (2mg/kg) was administered followed by a continuous rate
infusion (CRI) (fentanyl 7.5 µg/kg/hr and lidocaine 50 µg/kg/min) for the remainder of the
procedure.
2.2.4 Surgical Procedure
Two pigs received condylectomy only (1 in each treatment group) and twelve received
condylectomy and implant (6 in each treatment group). Briefly, a #10 blade was used to make a
5 cm skin incision in the left submandibular area. The incision was carried through the platysma,
cervical fascia and masseter muscle with electrocautery using blunt and sharp dissection. A
periosteal elevator was used to expose the ramus of the mandible from the mandibular angle to
the condyle. A premeasured osteotomy from the sigmoid notch was carried ventrally to the
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Figure 2.1 Technique for administration of nerve block: Nerve stimulation and block technique.
This dissection of a pig skull demonstrates the pathway of the mandibular nerve and the point at
which the block is expected to be administered. The mandibular nerve (black arrow) runs cranial
ventral from the foramen ovale toward the mandibular foramen. The needle attached to the
electronic nerve stimulator was advance from the angle of the mandible toward the lateral
canthus of the ipsolateral eye (white arrow) and medial to the ramus of the mandible. The white
dotted line indicates the edges of the removed portion of the ramus (R). The temporomandibular
joint is also labeled (T).
middle of the ramus where a horizontal osteotomy was created through the caudal border with a
reciprocating saw with copious irrigation. This segment of bone containing the condyle and a
portion of the ramus was then removed after dissecting the medial musculature. Bone implants
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similar in size and shape to the removed segment were secured in the space previously occupied
by the native ramus-condyle unit with Stryker-CMF miniplates and screws. Following copious
sterile saline irrigation, the masseter muscle, platysma muscle and subcutaneous tissue were
closed with #2-0 synthetic monofilament absorbable suture (Biosyn, Covidien; Mansfield, MA)
in respective layers. Skin edges were apposed with #2 nylon (Oasis; Mettawa, IL). All surgical
procedures were performed by oral and maxillofacial surgeons with the assistance of a boarded
veterinary surgeon.
2.2.5 Postoperative Pain Assessment
During recovery, pigs were monitored for signs of pain or discomfort (Table 1). Heart rate
(direct auscultation), respiratory rate (visual observation), appetite, urination, defecation,
ambulation, vocalization, non-purposeful movement and mentation were recorded every 15
minutes for 2 hours and then at 4 hours post extubation with first recording made at the time of
extubation. Subjective assessments (vocalization, ambulation, etc.) were assigned a numeric
value for statistical analysis. Time from end of surgery to extubation varied due to the need for
postoperative computer tomography scans and based on duration of recovery from anesthesia.
Assessment of all pigs was performed by a veterinarian who was blinded to treatment. If pigs
were noted to be painful by the observer a dose of buprenorphine (Reckitt Benckiser
Pharmaceuticals Inc; Richmond, VA) (30 ug/kg) was administered intramuscularly and then
every 8 hours as needed. Administration of buprenorphine was not based on ethogram score but
rather clinical evaluation by the veterinarian.
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Table 2.1 Postoperative Pain Ethogram:
Behavior
Appetite
Urination
Defecation
Ambulation
Vocalization
Non Purposeful
Movement
Mentation

Score
0
None
0
None
0
None
0
Recumbant
0
None
0
None
0
Nonresponsive

1
Mild
1
Urine
1
Feces
1
Uncoordinated
1
Grunt
1
Mild
1
Obtunded

2
Moderate

3
Aggressive

2
Sluggish
2
Whine
2
Moderate
2
Dull

3
Normal
3
Squeal
3
Violent
3
Quiet

4
Hyperactive

4
Bright

5
Hyper-responsive

A custom ethogram was used to assess clinical pain in pigs postoperatively. Assessments were
completed every 15 minutes for the first 2 hours after extubation with a final reading at 4 hours
after extubation.
2.2.6 Statistics
Mean values and standard deviations were calculated from continuous BP and HR data within
segments corresponding to 1 minute before the surgical incision (baseline), 1 minute prior to
rescue analgesia (pre-rescue) and for 1 minute at 10 and 20 minutes post rescue (10 minutes
post-rescue and 20 minutes post-rescue, respectively). Repeated measures analysis of variance
was used to compare hemodynamic parameters between treatment groups and time points (NCSS
8 Version 8.0.13, NCSS LLC, Kaysville, Utah). Tukey’s post-hoc analysis was performed to
assess statistically significant differences. Time to rescue and postoperative pain scores were
analyzed using a second statistical package (MYSTAT Version 12.02.00, Chicago, IL).
Student’s t test was used to compare times to rescue and postoperative pain scores. Significance
was set at p ≤ 0.05.
2.3

Results

For purposes of this study variations in BP and HR were used to represent responses to painful
stimuli (64, 71, 72). All pigs were maintained on 1.5% isoflurane throughout the procedure,
received a constant intravenous fluid rate of 5ml/kg/hr, and had minimal blood loss.
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2.3.1 Time to Rescue
A total of 8 pigs were included in the statistical analysis (n= 5 bupivacaine cohort; n= 3 saline
cohort), all of which required rescue analgesics intraoperatively. There was no difference in time
until rescue (p=0.84) between the bupivacaine and saline groups (Figure 2).

Figure 2.2: Mean ± SEM time from start of surgery until rescue analgesics (fentanyl/lidocaine)
were administered based on predetermined BP and HR changes. Differences between treatment
groups were not significant (P = 0.84).
2.3.2 Hemodynamic Parameters
A total of 8 pigs were included in the statistical analysis (n=5 bupivacaine cohort; n=3 saline
cohort). Mean BP differed significantly over time (p = 0.002) with the difference occurring
between the baseline and the pre-rescue time points for all pigs. No difference was seen between
the treatment groups overall. Within the bupivacaine group the mean pre-rescue BP was
significantly higher than baseline, 10 min post, and 20 min post (p=0.001) (Figure 3). No
differences were demonstrated between time points for the saline group.
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Figure 2.3: Perioperative blood pressure. (a) Mean ± SEM BP for the two treatment groups at
each of 4 time points. (b) Perioperative changes in BP by individual pig (bupivacaine group,
n=5; saline group, n=3). Pre-rescue BP (*) was significantly higher from other time points
within the bupivacaine group (P = 0.001).

Figure 2.4: Perioperative heart rate. (a) Mean ± SEM percent change in HR from baseline at
each of 3 time points for the two treatment groups. (b) Perioperative changes in HR by
individual pig (bupivacaine group, n=5; saline group, n=3). The HR was significantly lower in
the bupivacaine treatment group overall (P = 0.044) but not at any individual time point.
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On a percentage change basis, mean HR differed significantly between treatment groups
(p=0.044) with the bupivacaine group having a lower HR than the saline group (Figure 4). Posthoc analysis revealed no differences between time points within treatment groups.
2.3.3 Postoperative Pain Assessment
No difference was observed in postoperative parameters leading to buprenorphine injection for
pain (p = 0.13). 4 pigs (57%) in the saline group and 6 pig (86%) in the bupivacaine group
received buprenorphine injections within 3 hours of extubation (Figure 5). The only sign of pain
displayed by the pigs was an unwillingness to eat and frequent motion of the mandible not
associated with chewing. The two pigs which did not receive implants (split evenly between
treatment groups) began eating normally within 2 hours of extubation. All pigs ate normally
within 24 hours of extubation.

Figure 2.5: Time to buprenorphine injection after extubation. Differences between treatment
groups were not significant (P = 0.13).
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2.4

Discussion

The current study was designed to assess the efficacy of a mandibular nerve block as part of an
anesthetic regimen for porcine mandibular condylectomy surgery. Addition of a bupivacaine
mandibular nerve block resulted in significantly lower HR compared to a saline control at an
identical level of inhalant isoflurane anesthesia and systemic fentanyl analgesia. BP was
significantly reduced in the bupivacaine group after initiation of rescue analgesia while no
difference was noted in the saline control. As indicated in methods, BP and HR values up to the
end of the condylectomy procedure were used for statistical analysis. These findings support our
first hypothesis that a bupivacaine mandibular nerve block may decrease the need of systemic
analgesics during mandibular condylectomy surgery. Our second hypothesis of decreased
postoperative pain was not supported by the results. Based on the combined results of this study
and the common use of local blocks in human oral and maxillary surgery (58), a mandibular
nerve block is justified to improve patient comfort during surgery and thereby reduce potential
necessity for higher dosages of systemic analgesics.
The porcine model for oral maxillofacial surgical procedures is well established (54, 61, 73, 74).
Miniature pig jaw structure closely resembles that of the human jaw in terms of bone anatomy,
morphology, and healing (75). In the study reported here, the Yucatan miniature pig
condylectomy model was selected for evaluation of a therapeutic intervention for
temporomandibular joint disease. Animal models optimized to represent the human clinical
scenario contribute to information with the highest translational value. Local anesthesia through
nerve blocks of maxillary, mandibular, superficial cervical plexus, trigeminal and
sphenopalatine, among others, are commonly used for human oral and maxillofacial surgery
(58). Benefits in humans include improved perioperative analgesia, reduced preoperative
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opioids, and lower postoperative systemic analgesics (76-78). Based on this information, we
sought to improve the porcine mandibular condylectomy model with a more effective anesthetic
protocol. The results achieved by addition of the block to this porcine model are similar to those
reported for human patients using standard assessments of blood pressure and heart rate.
There are limitations to every animal model typically associated with size, conformation and
behavior (75). While the Yucatan pig generally has optimal size, they do differ significantly
from humans in several ways. Perhaps the most important are slight differences in jaw anatomy
and very thick skin that are most evident when trying to identify nerve block sites. This obstacle
was overcome by the use of a nerve stimulator. The use of nerve stimulation for accurate nerve
localization is a feasible option for most animal research surgical facilities.
The pig's stoic nature can make post-operative pain assessment challenging. Observational signs
of pain are often useful clinically but can be difficult to assess statistically. The lack of verified
pain assessment signs for swine in oral and maxillofacial studies makes this process even more
challenging. A custom ethogram was created specifically for the patients in this study and was
based on input from multiple veterinarians with swine experience. The ethogram used did not
detect a difference in behavior between groups. Increased jaw motion and reduced food
consumption were the only behaviors interpreted as evidence of pain. Many of the behaviors
being evaluated may have been affected by other variables besides pain itself. All variables in
observational pain studies should be controlled in order to eliminate the possibility of
confounding results. Evaluating the pigs from time of extubation made differentiating signs of
pain and recovery from anesthesia difficult.
It is standard practice to control postoperative pain with non-steroidal anti-inflammatory drugs
(NSAIDs). However, NSAIDs are controversial in research surrounding bone formation and
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stem cell osteogenic capabilities since the anti-inflammatory properties have been shown to
delay bone healing and stem cell differentiation (79-82). Other analgesics like opioids require
frequent administration which may cause increased stress and make the animals averse to
handling. Long acting regional anesthesia is a potential alternative, but there is limited published
information on this approach in swine. The local nerve block seemed to improve pain control
under anesthesia in combination with lidocaine/fentanyl CRI. Local nerve blocks are commonly
used in human medicine for surgical procedures on the mandible and maxilla and they have been
shown to improve postoperative pain management (58, 76, 77, 83-85). The increasing use of
swine models for oral and maxillofacial surgical research justifies further investigation into the
effectiveness of local nerve blocks.
Duration of action of local nerve blocks varies with the use of different local anesthetic drugs
(86). Indwelling catheters have even been placed in humans to provide a continuous block for
control of mandibular pain (87, 88). Bupivacaine reportedly provides local analgesia for 2 to 12
hours depending on the species (59, 60, 89, 90). It has been shown to be effective in relieving
mandibular pain for up to 12 hours between infusions in humans when given through an
indwelling catheter (87, 88). The lack of pain control postoperatively in this study may have
been due to lack of duration, variation in time lapse from block to extubation, the low animal
numbers, discomfort from implant, or failure of block to provide postoperative pain. The
addition of drugs such as epinephrine has been shown to increase local anesthetic duration (89,
91). By adding epinephrine or utilizing a long acting local anesthetic such as liposomal
bupivacaine, the duration of the local block may increase and be evident in the postoperative
period.
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The mandibular nerve block is a simple addition to the anesthetic regimen in the miniature pig
condylectomy model that may improve analgesia. While locally blocking the mandibular nerve
improved surgical analgesia in this study, a bupivacaine nerve block should not be the sole
means of pain management. Systemic analgesics are required for proper pain control. Further
studies and larger animal numbers are needed to better assess the intraoperative and postoperative effects of a mandibular nerve block in the porcine mandibular condylectomy model.
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CHAPTER 3: ADULT ADIPOSE DERIVED MULTIPOTENT STROMAL CELLS
ALTER SYSTEMIC T CELL POPULATIONS AND BIOMARKER LEVELS OF BONE
METABOLISM FOLLOWING FACIAL IMPLANTATION OF BONE XENOGRAFTS
IN A PORCINE MODEL.
3.1

Introduction

Adult multipotent stromal cells (MSC) are a central component of regenerative medicine,
including the area of bone generation(92). Adipose tissue is an easily accessible and plentiful
source of MSCs, adipose-derived multipotent stromal cells (ASCs) that has a number of
advantages over bone marrow including higher MSC density and greater plasticity (2, 11, 93-95).
Implants composed of ASCs on biocompatible scaffolds provide an appealing alternative to
address limited supplies and potential complications of autologous and autogenous bone graft
tissues. Scaffolds are generally composed of materials with compositions and microarchitectures
designed to recreate the target tissue microenvironment (96-98). Following cell loading onto the
scaffolds, culture environments are created to direct undifferentiated cell commitment to the
target tissue lineage (99). At present, there are a number of proposed mechanisms by which
scaffolds with cells demonstrate better in vivo osteogenesis than those without (100). Table 3.1
is a reference for all acronyms used in this manuscript.
Serum biomarkers are used to detect and quantify bone resorption, deposition and cell metabolic
activity characteristic of conditions like menopause, neoplastic bone metastasis, and
osteoarthritis (48, 50, 51, 101) A number of bone biomarkers have been validated for use in
large animal models, including porcine (51). To date, use of the biomarkers to evaluate
alterations in bone activity mediated by ASCs implantation has not been extensively tested. Use
of biomarkers may provide a valuable mechanism to compare alterations by cell therapies for a
number of clinical targets, including bone healing and deposition.
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Table 3.1 Acronyms
APC
ASC
BAP
BMP
CBC
CPII
CS 846
GVHD
ICTP
IDO
IL-(#)
PYD
MHC
MSC
NI
TNF-β

Acronyms
Antigen Presenting Cell
Adipose Derived Multipotent Stromal Cell
Bone Specific Alkaline Phosphatase
Bone Morphogenic Protein
Complete Blood Count
C-propeptide of type II collagen
Chondroitin sulfate epitope 846
Graft-vs-host disease
C-terminal telopeptide of type I collagen
Indoleamine 2,3-dioxygenase
Interleukin
Pyridinoline cross links
Major Histocompatibility Complex
Multipotent Stromal Cells
No implant
Transforming Growth Factor Beta

Recent information supports that ASCs modulate the immune response to graft materials and
improve integration of foreign materials into recipients (102, 103). ASCs are reported to
suppress T and B cell activation by a number of mechanisms (16, 24, 35, 104, 105). Xenogeneic
transplants result in T cell stimulation due to presentation of donor major histocompatibility
complex (MHC) molecules by antigen presenting cells (APC) from either the recipient (indirect)
or the donor (direct) (103). Research has largely focused on ASC alteration of the local response
to xenogenic material in vitro and in vivo (106, 107). Systemic immune effects of ASCs are
suggested by their effective us for treatment of graft-versus-host and auto-immune diseases
(16)(17, 18, 108)(19, 21). However, the ability of ASCs to effectively “mask” xenogeneic
implant materials from the immune system based on a systemic response is largely unexplored
(16). Enhanced osteogenic capabilities conferred by graft materials like growth factors, cell
signals, and structural support are diminished by active immune response to the implant (44,
103). It is also possible that sensitization resulting from local reaction to foreign graft materials
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may reduce efficacy and safety of subsequent implant administration. Mechanisms to reduce the
systemic response to graft materials will increase options, improve outcomes and reduce safety
concerns.
This series of investigations was designed to evaluate the systemic effects of ASC implantation
on custom bone xenografts in a Yucatan miniature swine mandibular condylectomy model. The
mandibular condyle was extracted or replaced with custom, deproteinated bovine
corticocancellous bone grafts with or without autologous ASCs. Blood samples were collected
before and up to 6 months after surgery and serum levels of bone biomarkers were quantified.
Relative percentages of Cytotoxic T cells, T helper cells, and B cells were determined based on
cell surface expression of CD3, CD4, CD8, and CD21. The hypothesis tested was that
implantation of xenogeneic bone implants with autologous ASCs: (1) will decrease the
circulating recipient T cells post-implantation compared to deproteinated xenograft alone; (2)
will alter the levels of serum biomarkers of osteogenesis consistent with improved bone
formation compared to no implant and deproteinated xenograft; (3) will increase the surface area
and bone volume at the surgical site compared to no implant and a deproteinated xenograft alone.
3.2

Materials and Methods
3.2.1 Study Design

Fourteen pigs were assigned to one of three treatment cohorts prior to mandibular condylectomy:
no implant; bovine corticocancellous implants and custom corticocancellous bone graft with
autologous ASCs. Culture expanded ASCs from subcutaneous adipose tissue were seeded onto
bovine cancellous xenografts machined in the shape of the mandibular condyle derived from
computed tomography images. Constructs were maintained in a bioreactor culture system.
Serum and peripheral blood mononuclear cells (PBMCs) were isolated from blood samples
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collected at regular intervals up to 6 months after surgery. Serum and PMNCs were
cryopreserved and subsequently, systemic lymphocyte phenotypes percentages were quantified
with flow cytometry and biomarker levels were determined with commercially available enzyme
linked immunosorbant assays (ELISA’s). Bone volume and surface area was measured on 3-D
reconstructions generated from computed tomography scans.
3.2.2 Animals and Husbandry
This study was performed at the Louisiana State University School of Veterinary Medicine, an
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
International accredited facility, in accordance with the Guide for the Care and Use of
Laboratory Animals. All experimental procedures were approved by the Institutional Animal
Care and Use Committee.
Fourteen male castrated Yucatan miniature pigs (Sus scrofa domestica) were purchased and
certified to be current on Mycoplasma hyopneumoniae bacterin (M + Pac) vaccine and free from
common domestic swine diseases (leptospirosis, brucellosis, pseudorabies, transmissible
gastroenteritis, porcine reproductive respiratory syndrome and toxoplasmosis) by the supplier,
Sinclair Bio-Resources (Columbia, MO). All pigs were skeletally mature upon arrival at the
institution (mean age, 24.7 months; range, 20 to 32 months). They were housed in groups of 4 to
5 in an ambient temperature facility. Pens in which they were housed measured 124 inch by 84
inch with rubber padded flooring covered by about 2 inches of pine shavings (S&S Farms, Inc.,
Franklinton, LA). A radiant heat source was supplied when ambient temperatures dropped
below 50°F (10°C). Pigs were offered Mazuri® Mini Pig Active Adult #5Z91 diet (Land
O’Lakes, Inc., Saint Paul, MN) twice daily in one trough per two pigs, and they had unrestricted
access to water for the duration of the study. Pigs were allowed to acclimate to their new
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environment for 7 days prior to initiation of the study, and they were housed singly for
approximately 18 hours after surgery before being returned to their established social groups.
3.2.3 Experimental Groups
All pigs were scheduled to undergo a left mandibular codylectomy procedure. Prior to surgery,
pigs were blindly assigned to one of three treatment groups: no implant (Control), bovine
cancellous bone scaffold only (Scaffold), and bovine cancellous bone scaffold with autologous
ASCs (ASC). Pigs assigned to the Cell group had subcutaneous adipose tissue harvested from
their dorsums for adult mesenchymal cell collection.
3.2.4 Adipose Tissue Harvest
Supra-gluteal subcutaneous adipose tissue was aseptically harvested with pigs under general
anesthesia. Pigs were premedicated (Telazol® (Zoetis, Kalamazoo, MI), 2mg/kg
intramuscularly) and after 20 minutes anesthesia was induced with isoflurane (MWI, Boise, ID)
via face mask followed by maintenance with isoflurane via endotracheal tube in a semi-closed
rebreathing circuit.. Pigs were positioned in sternal recumbency and the dorsal lumbar area was
clipped and aseptically prepared by alternating chlorhexidine and ethyl alcohol scrubs.
Approximately 15 ml of adipose tissue was sharply excised through each of two paralumbar skin
incisions approximately 5 cm from midline. Hemostasis was maintained with electrocautery.
Following tissue harvest, incision sites were thoroughly lavaged with saline. Skin was
approximated with #2 polydioxanone (PDS, Ethicon, US) in a simple continuous
subcutaneous/subcuticular suture pattern. Interrupted skin sutures of #1 nylon (Ethilon®,
Ethicon, US) were then placed and the incision was sealed with tissue adhesive (Vetbond™, 3M,
US). Incision sites were covered with iodine impregnated adhesive drapes (Ioban™, 3M) prior
to recovery.

28

3.2.5 ASC Isolation
ASCs were isolated as previously described (109). Briefly, adipose tissue was minced with
metzenbaum scissors, washed and agitated with phosphate-buffered saline (PBS). The tissue was
digested in filtered PBS solution containing 1% bovine serum albumin (BSA) and 0.1% of
collagenase with continuous shaking for 50 minutes. Subsequently samples were centrifuged at
300 g for 5 minutes. Samples were again agitated and centrifuged. The supernatant was removed
and the stromal-vascular fraction (SVF) pellet was resuspended in 10mL stromal medium
(Dulbecco’s Modified Eagle Medium/Ham’s F-12 Nutrient Broth (1:1), fetal bovine serum
(FBS), and Penicillin/Streptomycin/Fungizone). Samples were again agitated and centrifuged.
Supernatant was aspirated off leaving 5 ml of medium on each pellet. Pellets were resuspended
in a total of 105 ml stromal media per 100 ml of adipose tissue digest.
3.2.6 Bioengineered Autologous Grafts
Cells were plated in cell culture flasks at a concentration of approximately 35 ml per
225cm2 flask. Media was changed after 24 hours to wash away non-adherent cells and replaced
with expansion medium (stromal medium with the addition of human epidermal growth factor
(rhEGF), recombinant human fibroblastic growth factor (rhFGF), and transforming growth factor
beta-1 (TGF-β1)). The expansion media was changed every 3 days until day 7 to complete one
passage. After each passage the expansion media was aspirated off and flasks were washed
gently with 20 ml PBS. 8 ml of trypsin/T225 was added and the flask was incubated for 5
minutes at 37ºC. After incubation, 8 ml of stromal medium was added to inactivate trypsin. 16
ml of trypsin/stromal medium was collected and centrifuged at 300 g for 5 minutes. Medium was
aspirated off. Cells were passaged 3 times.
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Bone implants were prepared using a method previously described (97). Biefly, trabecular bone
was collected from the distal femur of calves and lathed into cylinders. A computer tomography
(CT) image of the skull of each pig was taken (Figure 3.1). A 3D reconstruction of the skull was
made from the CT images using Mimics 9.0 and MasterCam computer-aided-manufacturing
(CAM) was used to design and fabricate a scaffold and bioreactor chamber. Implant fabrication
was done using a Bridgeport three-axis computer-numerical-control milling machine.
Grafts were decellularized using, in order, a combination of; high-velocity streams of water, 1
hour wash in PBS with 0.1% EDTA, washes in hypotonic buffer (10mM Tris, 0.1% EDTA)
overnight at 4⁰C, detergent (10mM Tris, 0.5% SDS) for 24 hours at room temperature, and
enzymatic solution (50 units/mL DNase, 1 units/mL RNase, 10mM Tris) for 3-6 hours at 37⁰C.
Grafts were then rinsed repeatedly with PBS and freeze-dried. Prior to seeding cells, grafts were
sterilized in 70% ethanol for 1 hour, rinsed in PBS, and incubated in culture medium overnight.
Cell seeding was done using previously collected ASCs suspended in culture medium at a

Figure 3.1 3 Dimensional Reconstruction: The CT images take at the beginning of the study
were used to construct the cancellous implants. The portion of the ramus and condyle to be
removed and replaced with an implant is stipled in purple.
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density of 106 cells per ml. Grafts were suspended in cell suspension for 1 hour at 37⁰C while
suspension was stirred at 300 rpm. Grafts were then placed into osteogenic medium, with daily
medium changes. After 7 days, grafts were placed into custom bioreactor chambers and perfused
at 1.8 ml/min for 4 weeks. Media was changed at a rate of 50% every 3 days.
3.2.7 Surgical Protocol
Pigs were chemically restrained with ketamine (10mg/kg, Vedco Inc.; St. Joseph, MO),
midazolam (0.2mg/kg, Hospira, Inc.; Lakeforest, IL), and dexmedetomidine (2ug/kg, Pfizer
Animal Health, NY, NY) administered intramuscularly. Fifteen minutes later, anesthesia was
induced with 5% isoflurane in 100% oxygen via facial mask. When muscle relaxation
characterized by loss of jaw tone and palpebral reflexes was observed, the trachea was intubated
with a cuffed Murphy’s endotracheal tube (7-9 mm internal diameter). Anesthesia was
maintained in all pigs with isoflurane in a circular breathing system until the end of the surgery.
Pigs were monitored throughout the procedure by a boarded veterinary anesthesiologist.
Pigs were placed in right lateral recumbency and the left jaw surgically prepped with alternating
scrubs of chlorhexidine and 70% isopropyl alcohol and draped. Two pigs received
condylectomy only and twelve received condylectomy and implant (6 in each treatment group).
Briefly, a #10 blade was used to make a 5 cm skin incision in the left submandibular area. The
incision was carried through the platysma, cervical fascia and masseter muscle using blunt and
sharp dissection. A periosteal elevator was used to expose the ramus of the mandible from the
mandibular angle to the condyle. A premeasured osteotomy from the sigmoid notch was carried
ventrally to the middle of the ramus where a horizontal osteotomy was created through the
caudal border with a reciprocating saw with copious irrigation. This segment of bone containing
the condyle and a portion of the ramus was then removed after dissecting the medial
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musculature. Bone implants similar in size and shape to the removed segment were secured in
the space previously occupied by the native ramus-condyle unit with two 1.7mm titanium Lorenz
bone miniplates (Stryker, US) and 8 screws (range 6-12mm). Following copious sterile saline
irrigation, the masseter muscle, platysma muscle and subcutaneous tissue were closed with #2-0
synthetic monofilament absorbable suture (Biosyn, Covidien; Mansfield, MA) in respective
layers. Skin edges were apposed with #2 nylon (Oasis; Mettawa, IL). Incision sites were
covered with iodine impregnated adhesive drapes (Ioban™, 3M) prior to recovery.
3.2.8 Blood Collection
Venous blood (30 mL) was collected from the cranial vena cava of each pig pre-operatively,
once weekly for first 4 weeks after surgery and then every 3 weeks thereafter until the end of the
study (Table 3.2). Baseline blood samples were collected when pigs were chemically restrained
for surgery. Postoperative blood was collected under chemical sedation using Telazol® at a
dosage of 2 mg/kg given intramuscularly. All blood was collected by pre-caval blood collection
technique while pigs were dorsally recumbent with an 18g, 1.5” needle. Blood samples were
divided equally by value between EDTA tubes, lithium heparin tubes, and serum separator gel
tubes.
3.2.9 Complete Blood Counts:
Blood collected into an EDTA tube was supplied to the clinical pathology department at the
Louisiana State School of Veterinary Medicine. The blood was analyzed within 6 hours of being
collected. An ADVIA 120 (Siemens, Tarrytown, NY) was used for the initial hematology using
veterinary specific software. Differentials were manually calculated from a 100 cell sample.

32

Table 3.2 Blood Collection
Pre-op
1
2
3
Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

4

7

10

13

16

19

22

25

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Flow
ELISA
CBC

Blood collection timeline by weeks. Blood was used for flowcytometry (Flow) at each blood
draw. Blood was used for analysis of bone biomarkers (ELISA) approximately every 3 weeks.
3.2.10 Serum and Plasma Cryopreservation
Serum separator gel tubes were allowed to sit for 30 minutes for blood samples to clot before
centrifugation. Both lithium heparin and serum separator gel tubes were placed into a centrifuge
and spun for 10 minutes at 1,000 x g (gravity). Serum and plasma samples were pipetted from
their respective tubes and placed in labeled vials. The vials were placed in to an alcohol free
controlled rate -1°C/minute cell freezing container (CoolCell®, biocision) in a -80⁰C freezer.
After 24 hours, were transferred to liquid nitrogen storage.
3.2.11 PBMC Isolation, Counting, and Cryopreservation
PBMCs were isolated, counted, and cryopreserved using a previously described method (110).
EDTA tubes were centrifuged for 10 minutes at 1,000 x g. After centrifugation the buffy coat
was pipetted out of the tubes, along with approximately 3 mL of red cells and serum, and placed
into a 15mL graduated tube. An equal volume of FBS was added to the sample and mixed well.
Blood mixture was carefully pipetted on top of 3 mL of Ficoll-Hypaque (GE, Piscataway,NJ)
solution in a separate 15mL tube. The tube was then centrifuged at 400 x g for 30 minutes. After
centrifugation, the buffy coat (PBMC layer) was transferred by pipette to a new 15mL tube and
washed with approximately 10mL of PBS. The tube was centrifuged again at 400 x g for 10
minutes. Thereafter, the supernatant was removed and cells were resuspended in 5mL of red cell
lysis buffer for 3 minutes. Tubes were then filled with PBS and centrifuged at 400 x g for 10
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minutes. Supernatant was removed and 10mL of PBS was added to tubes. Cells were then
resuspended for counting of viable PBMCs.
10 uL of PBMC suspension was placed into a 500uL culture tube. 90 uL of 0.4% trypan blue
stain was added and mixed by pipetting thoroughly. A hemocytometer was loaded with 10uL of
the stained cells and PBMCs were counted at 40x magnification for calculation of PBMCs/ml.
The PBMC suspension was centrifuged again and supernatant was removed. Cells were diluted
in 90% PBS and 10% DMSO solution to a concentration of no greater than 1x10^7 cells/ml.
Cell suspensions were pipetted into cryopreservation tubes which were placed in a CoolCell and
put in a -80⁰C freezer for cryopreservation. After 24 hours, tubes were transferred to liquid
nitrogen storage.
3.2.12 Serum Biomarker ELISAs
Serum samples were removed from -80°C freezer and allowed to thaw at room temperature prior
to running ELISAs. Commercially available ELISA kits were purchased to analyze serum
biomarker levels (Table 3.3). All kits had been previously validated for use in swine (51).
Instructions and reagents provided in kits were used for serum analysis. Plates were read on a
Synergy HT Multi-Mode microplate reader (BioTek, Winooski, VT) at recommended settings.
Manufacturer’s instructions are provided in the appendix section (additional files 1-6).
3.2.13 PBMC Preparation for Flow Cytometry Analysis
Cryopreserved PBMCs were thawed as previously described. Briefly, cryovials were removed
from -80⁰C freezer and placed into 37⁰C bead bath. Cell suspension was then transferred to 15cc
tube and thawing media (90% RPMI (Roswell Park Memorial Institute) Media (Sigma-Aldrich,
St. Louis, MO), 10% FBS (fetal bovine serum)) was slowly added over time with a pipette. The
tube was centrifuged and cells were washed in 10mL of RPMI. After a second centrifugation
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Table 3.3 ELISA Kits used for assessment of serum biomarkers of bone remodeling.
ELISA Kit
N-MID Osteocalcin ELISA
(Immunodiagnostic Systems, Scottsdale, AZ)
CPII ELISA
(IBEX Pharmaceuticals Inc., MONT-ROYAL, Quebec)
CS 846 ELISA
(IBEX Pharmaceuticals Inc., MONT-ROYAL, Quebec)
MicroVue BAP ELISA
(Quidel Corp., San Diego, CA)
MicroVue Serum PYD EIA
(Quidel Corp., San Diego, CA)
UniQ ICTP EIA
(Orion Diagnostica, Finland)

Biomarker Measured
Osteocalcin
C-propeptide of type II collagen
(CPII)
Chondroitin Sulfate epitope 846
(CS 846)
Bone Specific Alkaline Phosphate
(BAP)
Pyridinoline cross links
(PYD)
C-terminal Telopeptide of Type I
Collagen (ICTP)

cells were resuspended in FBS and cell concentration was determined as previously described.
Four directly conjugated antibodies were purchased for PBMC surface marker labeling with flow
cytometry. Antibodies used include; PerCP-Cy 5.5 Mouse Anti-Pig CD4a (BD Biosciences, San
Jose, CA), FITC Mouse Anti-Pig CD3ɛ (BD Biosciences, San Jose, CA), PE Mouse Anti-Pig
CD8a (BD Biosciences, San Jose, CA), and APC Mouse Anti-Human CD21 (BD Biosciences,
San Jose, CA). PBMCs were labeled with the following procedure. Equal amounts of each
sample (5x10^5 cells) were diluted into 300µL of PBS. Each sample had an unlabeled control
tube (no antibiodies) and a sample tube for antibody labeling. One µL of each antibody solution
was pipetted into the sample tubes (except CD21, 5µL was used). All tubes were incubated in
the dark for 20 minutes. After incubation, each tube was washed with 2mL PBS followed by
centrifugation for 5 minutes. The supernatant was removed and 30µL of 1% formalin was added
to each tube. All tubes were placed in 4⁰C fridge until processing. Processing occurred within
24 hours of fixation.
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3.2.14 Flow Cytometry Analysis
Samples were acquired on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA)
utilizing a 488 nm argon-ion laser and a 635 nm red diode laser and configured for FITC, PE,
PerCP-Cy5.5 and APC fluorescence measurements using log amplification. Samples were
acquired on a Macintosh G5 workstation (Apple Computer, Cupertino, CA) running Cellquest
Pro software (BD Biosciences, San Jose, CA). Cell debris was eliminated by gating on intact
cells based on dot plots of forward scatter versus side scatter. Dual fluorescence analyses in the
form of dot plots were illustrated using Cellquest Pro software (BD Biosciences, San Jose, CA).
Percentages of cells expressing CD3+, CD4a+, CD8a+, and CD21+ subsets were determined for
each sample based on comparisons with negative controls. Samples were tagged with all 4
antibodies at the same time. Figure 3.1 and Table 3.4 explain the cell phenotypes associated
with the evaluated surface markers. All values were normalized by division of postoperative
values by the preoperative value.

Figure 3.1 Cell Sorting by Flow Cytometry:
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Table 3.4 Cell Phenotypes

3.2.15 Bone Volume and Surface Area Measurements
Computer tomography scans were completed on the head of each pig at 5 time points:
preoperative, postoperative, 6 weeks, 3 months, and 6 months postoperative. 4 pigs (2 from ASC
and 2 from scaffold group) did not receive 6 month postoperative CTs. Digital 3D
reconstruction of the skull was done using Mimics x64 version 15.01 (Materialise, Plymouth,
MI). The left mandible was isolated for evaluation of volume and surface area. The evaluated
area was defined by a vertical line at the caudal aspect of the last molar to the caudal edge of the
mandible. Volume and surface area measurements were normalized to preoperative values for
analysis by subtracting postoperative time point measurements from peroperative measurements.
3.2.16 Statistical Analysis
Flow cytometry results were analyzed for 9 combinations of cell markers: CD3+/CD21-; CD3/CD21+; CD3-/CD21-; CD4+/CD3+; CD4+/CD8+, CD4+/CD8+; CD4+/CD8-, CD4-/CD8+.
Repeated measures analysis of variance (RMANOVA) in a mixed effects model was used to
compare raw and normalized percentages of cell populations between treatment groups and time
points. Fixed effects included treatment, time, and the treatment by time interaction. The
random effect was pig within treatment group. Raw and normalized serum biomarker levels
were analyzed using RMANOVA. Data was normalized by dividing each time point by
baseline. To stabilize variance terms, CS846 and CPII values were natural log transformed and
37

also assessed. Bone surface area and volume were normalized to preoperative levels and
evaluated using RMANOVA. Correlations between biomarker levels and bone volume, surface
area (SA), and volume:SA ratio measurements were run using Spearman and Pearson
Correlation Coefficients, as appropriate. Significance was set at p ≤ 0.05. Statistical analysis
was performed using SAS version 9.3 (SAS Institute, Cary, NC) Mixed and Corr procedures.
3.3

Results
3.3.1 Flow Cytometry

The effect of treatment on lymphocyte percentages was significant with all time points
considered together (Table 3.4). The ASC cohort had significantly lower percentages of Th cell
immunophenotypes CD4+/8-, CD4+/8+, and CD3+/4+ when compared to the scaffold cohort
(Figure 2). The NI group had significantly lower percentages of Th cell immunophenotypes
CD4+/8- and CD4+/8+ than the scaffold cohort (Figure 3.2).
3.3.2 Complete Blood Count
No significant differences were demonstrated between treatments or time points for lymphocyte,
neutrophil, or total white blood cell counts.
3.3.3 Serum Biomarkers
The effect of treatment on serum biomarker levels was significant with all time points considered
together (Table 3.6). Both ASC and scaffold groups had higher levels of BAP than the NI group.
ICTP was higher in the ASC group than both the scaffold and NI groups. Osteocalcin levels
were lower in the ASC group than NI (Figure 3.3).
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3.3.4 Bone Volume and Surface Area
Normalized bone SA and volume demonstrate differences among treatments when all time points
are considered together.. Volume was significantly lower in the NI group compared to the ASC
group (p=0.0041) (Figure 3.4 B). Surface area was significantly lower in the NI group compared
to both ASC and scaffold groups (p<0.0001) (Figure 3.4 A). No differences were demonstrated
between ASC and scaffold groups. No significant correlations were demonstrated between serum
biomarker values and bone volume or surface area measurements.
Table 3.5: Normalized Cell Population Differences by Treatment
Cell Population

Treatment Differences

P Value

CD 3-/21-

ASC > NI

0.0452

CD 3+/4+

ASC < S

0.0007

CD 4-/8-

ASC > NI, S

0.0009

CD 4+/8-

S > ASC, NI

0.0248

CD 4+/8+

S > ASC, NI

0.0062

T cell subset populations were evaluated in peripheral blood by flow cytometry. Cell
populations were normalized to equivalent base line value and evaluated for differences.
Statistical significance was set at p≤0.05.

Table 3.6: Normalized Biomarker Differences by Treatment
Biomarker

Treatment Differences

P Value

BAP

NI > S, ASC

0.0008

ICTP

ASC > S, NI

0.0129

Osteocalcin

ASC < NI

0.0179

Biomarker levels in serum were evaluated by commercially available ELISA kits. Serum levels
were normalized to equivalent base line values and evaluated for differences. Statistical
significance was set at p≤0.05.
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Figure 3.2 Significant differences in normalized T cell populations by treatment. Peripheral T
cell subset populations were evaluated using flow cytometry between 3 treatment groups; No
implant (NI), Scaffold, and Adipose Stromal Cells (ASC). Raw data was normalized to
equivalent base line values. Statistical differences are denoted with an asterisk (*) or letters
symbolizing if a difference was only seen between 2 of the 3 treatment groups. Statistical
significance was set at p≤0.05 and error bars represent SEM.
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Figure 3.3: Significantly different normalized serum biomarker levels between treatments.
Serum biomarker levels were evaluated using commercially available ELISA kits. Raw data was
normalized to equivalent base line values. Differences between treatments is denoted with an
asterisk (*). The bar graphs depict mean value over all time points by treatment groups. The
line graph shows variation in biomarker levels over time by treatment among which there were
no significant differences. Statistical significance was set at p≤0.05 and error bars represent
SEM.
41

Figure 3.8: Significant differences by treatment in normalized bone surface area and volume.
Bone surface area (SA) and volume was evaluated using computerized tomography scans at 4
time points. Measurements were normalized to preoperative baseline values. Significant
differences are denoted by the letters “a” and “b” over the bar graphs. The bar graphs depict the
mean values over the course of the study. The line graph shows the variation in SA and volume
over time between treatments which had no significance. Statistical significance was set at
p≤0.05 and error bars represent SEM.
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3.4

Discussion

The immune modulating and osteogenic effects of ASCs are very well described through in vitro
models and in vivo rodent models (2, 24, 30, 94, 107). The ability to evaluate the effect of ASC
in vivo through blood values and noninvasive imaging is a tremendous advantage when it comes
to clinical application. It can allow for better data collection and understanding of the use of
ASCs in large animal models and in the clinical setting. The effects of treatment on systemic
lymphocyte subpopulations and serum biomarkers of bone remodeling can be detected on a
systemic level. The lower levels of systemic Th cell populations with the use of ASCs mimics
results found in previous in vitro studies and on the local tissue level in vivo (16, 23, 29, 111)
and contributes to acceptance of the first hypothesis. The hypothesis involving biomarkers and
bone measurements could not be accepted as an increase in bone deposition could not be
confirmed through CT images and biomarker values did not demonstrate a definitive picture of
bone deposition. The results help to expand the available avenues for evaluating the use of
ASCs in bone regeneration.
Regulation of the T cell response is a crucial part of graft acceptance. Autografts are the gold
standard in bone grafts due in part to their lack of immune response. Unfortunately, lack of
supply and donor site morbidity make this types of grafts impractical in large reconstructive
surgeries. Allografts from cadavers are more common but come with complications of immune
response and possible disease transmission. Engineered bone grafts using autologous ASCs and
cancellous bone xenografts demonstrate the ability to replicate the biological benefits of the
autograft with a possible limitless supply. The current study demonstrated a decrease in
circulating Th cell population in ASC treated graft groups compared to empty grafts in an in vivo
model. This is a novel approach for assessing the immune response to a local treatment with
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ASCs. Most in vivo models assess the T cell response to MSCs by evaluating tissue samples
post mortem through local tissue histopathology (35), immunohistochemistry, and PCR (107).
The suppression of Th cell proliferation in the current study agrees with results of previous in
vitro and in vivo studies (20, 25, 112).

The mechanisms behind the immune modulatory effects

of ASCs have been shown to include indoleamine 2,3-dioxygenase (IDO), prostaglandin E2,
transforming growth factor-beta (TGF-β), interleukin-10 (IL-10), nitric oxide, and others. This
wide range of elements gives support to the idea that ASCs can exploit different mechanisms in
different situations. The effects of treatment on Th cell populations on the systemic level in this
study help to validate this novel approach in assessing ASCs in tissue regeneration in vivo.
The use of systemic biomarkers for bone and cartilage metabolism to monitor clinical disease has
been looked at extensively in human medicine (52, 53, 113). The major areas of focus are for
osteoporosis, osteoarthritis, osteodystrophy, primary hyperparathyroidism, and neoplastic bone
metastasis. It is very feasible that similar markers can be used to assess possible differences in
osteogenesis between bone graft materials. The ability to correlate detectable changes in
biomarkers with clinical alteration is bone metabolism has been best described in regard to
neoplasia. Zhoa et al. found that patients with bone metastasis had significantly higher levels of
ICTP, procollagen type I N-terminal propeptide (PINP), BAP, and osteocalcin. These values
could even be correlated to the number of bone metastasis sites (114). Similar findings were
demonstrated in the current study in regards to ICTP being elevated in the ASC group. This is
suggestive of an increase in bone resorption. This can result from either recipient bone
resorption or remodeling of the xenograft. The lower levels of osteocalcin and BAP, in response
to treatment with ASCs compared to the NI cohort, is indicative of decreased osteoblast activity.
Decreases in osteoblast activity could result from decreased need for new bone formation (viable
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graft) or an inhibition of osteoblast activation. The possibility of mature bone deposition with
increased osteoclastogenesis and decreased osteoblastogenesis within the ASC cohort could also
explain the differences seen. Though definitive interpretation of the treatment effect on
biomarkers levels will require further studies, the ability to detect such effects is a step forward
in their use in research.
The assessment of ASC contribution to bone remodeling through CT scanning is common
practice in critical size defect models. The use of calvarian defects in rodents has been
successful in demonstrating the benefits of MSCs in scaffold implants (36-38). Large animal
models have also been used but generally evaluate a cylindrical defect in long bones (42, 74,
115). The current study was designed to look at replacing a large articulating defect which only
has direct contact to supporting bone on 2 edges. This presents more possibilities for
complications and fewer surfaces for osteoinduction and osteoconduction of the graft material.
A treatment effect was demonstrated on measurements of SA and volume when all time points
were considered together.

The lower measurements of SA and volume in the NI group would

suggest a decrease in bone formation. When the measurements of SA and volume are compared
by treatment for the final time point alone (6 months) no differences are demonstrated. Figure
3.5 demonstrates the similarities in bone growth at the surgical site between treatments at each
time point. The differences we were able to demonstrate during the study may have been
confounded due to the presence of the cancellous graft material. Histopathology of the surgical
sites was unavailable as they were used for a different study. Measurements of SA and volume
from CT evaluation may lack sensitivity for the comparison of bone growth in the current model.
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Figure 3.5: Computerized topography scans. Bone growth was evaluated throughout the study
by computerized topography scans of the surgical area. The 3 dimensional reconstructed area
was delineated cranially by the caudal aspect of the last molar and caudally by the caudal edge of
the ramus. The images used above are representative samples from each treatment group. There
were no differences between treatments in surface area or volume at the 6 month time point.

46

The present study demonstrates the ability to detect significant differences in circulating T cell
populations and bone biomarkers in a swine model for bioengineered cancellous bone grafts.
Lower population of systemic Th cells in the ASC group agrees with previous assessments of
ASCs abilities to suppress the T cell response and help validate the ability to detect these effects
on a systemic level. The effects on bone biomarkers evaluated in this study seem to indicate
more bone resorption in the ASC and scaffold groups compared to the control. These findings
were not supported by the CT evaluation of bone formation which showed no difference in SA or
volume between groups at the final time point. Treatment effects were evident in the biomarker
levels however interpretation of these effects requires further study. This study has given
validation to the ability to assess ASC effects in bone remodeling from a systemic view point.
Though further research is required in this area, the ability to detect treatment effect through
hematologic parameters can open the door to novel techniques and models in the use of ASCs.

47

CHAPTER 4: DISCUSSION AND FUTURE RESEARCH
The study of ASCs in tissue engineering is an exciting and expanding field. The potential use of
these cells for treatment of a wide variety of diseases and clinical problems is impressive. The
findings in this paper help us to better understand the use of such technology in a large animal
model and improve our understanding.
The inclusion of local nerve blocks in the veterinary medical field has expanded greatly in the
last decade. This also includes the area of animal models in research. Regulatory requirements
are focusing more on the wellbeing of the animals and avoidance of distress as our understanding
of animal behavior improves. The assessment of pain is very difficult in animals and varies
greatly amongst species. Our poor understanding of animal reactions to pain, within some
species, make it difficult for us to properly address the issue. Our findings in this study helped to
narrow the scope for pain assessment in pigs. Future studies in this area will be needed to
pinpoint possible behaviors associated with pain in this model. Studies assessing different and
possibly multiple nerve blocks are needed to add to the information presented here. The addition
of mean alveolar concentration (MAC) measurements in future studies will aid in eliminating
variation between subjects due to inhalant anesthesia. Though anatomically difficult for this
particular study, the use of electromyography (EMG) to aid in confirming nerve blocks would
greatly improve the viability of such studies.
The systemic evaluation of autologous ASC’s effects on bone xenograft implants are feasible
based on the data presented. Our findings may have raised more questions than answers but they
also opened the door for new modalities of assessing the effects of ASCs. The results point to
the ability of ASCs to prevent a Th cell response to the cancellous graft. Future studies may
attempt to further describe cellular populations through additional CD markers. Additional CD
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markers such as CD25 would help to address the idea that Treg cells are up regulated. The ability
to perform immunohistochemistry and histology on local lymph nodes and tissues in future
studies would greatly expand their scientific contribution.
The results further verify the use of certain biomarker ELISAs in pigs for the assessment of
orthopedic change which may help to elucidate the usefulness of these markers clinically.
Though the changes seen in the biomarkers where not correlated to the SA and volume
measurements in this study, they may correlate better with a more precise method of evaluating
bone growth. The use of nuclear scintigraphy or bone density could give more detailed
information regarding bone remodeling. Placement of metallic markers such as bone screws or
staples near the surgical sight could improve repeatability of such measurements and reduce
variability.
Overall these studies identified new techniques to improve and expand the use of the swine facial
reconstruction model. Our hope is that this will allow for a better understanding of the different
avenues in which ASCs function to enhance regenerative medicine.
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Additional File 2: Manufacturer’s instructions for the MicroVue Serum PYD EIA kit
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Additional File 3: Manufacturer’s instructions for the MicroVue BAP ELISA kit
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Additional File 4: Manufacturer’s instructions for the UniQ ICTP EIA kit
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Additional File 5: Manufacturer’s instructions for the CPII ELISA kit
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Additional File 6: Manufacturer’s instructions for the CS 846 ELISA kit
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